122 related articles for article (PubMed ID: 33271301)
1. Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.
D'Onofrio A; Gano L; Melo R; Mendes F; Oliveira MC; Denoël T; Schaefer N; Viertl D; Fierle J; Coukos G; Dunn S; Prior JO; Paulo A
Eur J Pharm Biopharm; 2021 Jan; 158():233-244. PubMed ID: 33271301
[TBL] [Abstract][Full Text] [Related]
2. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y; Hu J; Wang Y; Peng X; Min J; Wang J; Matthaiou E; Cheng Y; Sun K; Tong X; Fan Y; Zhang PJ; Kandalaft LE; Irving M; Coukos G; Li C
Eur J Cancer; 2018 Feb; 90():111-121. PubMed ID: 29304474
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation and Dosimetry of [
Cicone F; Denoël T; Gnesin S; Riggi N; Irving M; Jakka G; Schaefer N; Viertl D; Coukos G; Prior JO
Mol Imaging Biol; 2020 Aug; 22(4):979-991. PubMed ID: 31993928
[TBL] [Abstract][Full Text] [Related]
4. Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
Fierle JK; Brioschi M; de Tiani M; Wetterwald L; Atsaves V; Abram-Saliba J; Petrova TV; Coukos G; Dunn SM
Cell Rep Med; 2021 Aug; 2(8):100362. PubMed ID: 34467246
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.
Li C; Chacko AM; Hu J; Hasegawa K; Swails J; Grasso L; El-Deiry WS; Nicolaides N; Muzykantov VR; Divgi CR; Coukos G
Cancer Biol Ther; 2014 Apr; 15(4):443-51. PubMed ID: 24553243
[TBL] [Abstract][Full Text] [Related]
6. Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.
Zhao A; Nunez-Cruz S; Li C; Coukos G; Siegel DL; Scholler N
J Immunol Methods; 2011 Jan; 363(2):221-32. PubMed ID: 20837020
[TBL] [Abstract][Full Text] [Related]
7. Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.
Li C; Wang J; Hu J; Feng Y; Hasegawa K; Peng X; Duan X; Zhao A; Mikitsh JL; Muzykantov VR; Chacko AM; Pryma DA; Dunn SM; Coukos G
Oncotarget; 2014 Aug; 5(16):6994-7012. PubMed ID: 25051365
[TBL] [Abstract][Full Text] [Related]
8. Characterization of TEM1/endosialin in human and murine brain tumors.
Carson-Walter EB; Winans BN; Whiteman MC; Liu Y; Jarvela S; Haapasalo H; Tyler BM; Huso DL; Johnson MD; Walter KA
BMC Cancer; 2009 Nov; 9():417. PubMed ID: 19948061
[TBL] [Abstract][Full Text] [Related]
9. Anti-Endosialin Antibody-Drug Conjugate: Potential in Sarcoma and Other Malignancies.
Rouleau C; Gianolio DA; Smale R; Roth SD; Krumbholz R; Harper J; Munroe KJ; Green TL; Horten BC; Schmid SM; Teicher BA
Mol Cancer Ther; 2015 Sep; 14(9):2081-9. PubMed ID: 26184481
[TBL] [Abstract][Full Text] [Related]
10. Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.
Chacko AM; Li C; Nayak M; Mikitsh JL; Hu J; Hou C; Grasso L; Nicolaides NC; Muzykantov VR; Divgi CR; Coukos G
J Nucl Med; 2014 Mar; 55(3):500-507. PubMed ID: 24525208
[TBL] [Abstract][Full Text] [Related]
11. First clinical study of a pegylated diabody
Scott AM; Akhurst T; Lee FT; Ciprotti M; Davis ID; Weickhardt AJ; Gan HK; Hicks RJ; Lee ST; Kocovski P; Guo N; Oh M; Mileshkin L; Williams S; Murphy D; Pathmaraj K; O'Keefe GJ; Gong SJ; Pedersen JS; Scott FE; Wheatcroft MP; Hudson PJ
Theranostics; 2020; 10(25):11404-11415. PubMed ID: 33052222
[TBL] [Abstract][Full Text] [Related]
12. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
13. Role of tumor endothelial marker 1 (Endosialin/CD248) lectin-like domain in lipopolysaccharide-induced macrophage activation and sepsis in mice.
Cheng TL; Lin YS; Hong YK; Ma CY; Tsai HW; Shi GY; Wu HL; Lai CH
Transl Res; 2021 Jun; 232():150-162. PubMed ID: 33737161
[TBL] [Abstract][Full Text] [Related]
14. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
15. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
16. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration.
Tomkowicz B; Rybinski K; Foley B; Ebel W; Kline B; Routhier E; Sass P; Nicolaides NC; Grasso L; Zhou Y
Proc Natl Acad Sci U S A; 2007 Nov; 104(46):17965-70. PubMed ID: 17986615
[TBL] [Abstract][Full Text] [Related]
17. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A
Cancer Immunol Immunother; 2017 Mar; 66(3):367-378. PubMed ID: 27933426
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.
Leigh BR; Burke PA; Hong AM; O'Donnell RT; Howell LP; Miers LA; DeNardo GL; DeNardo SJ
Cancer Biother Radiopharm; 1999 Apr; 14(2):113-9. PubMed ID: 10850294
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
